PMOS (polyendocrine metabolic ovarian syndrome) is the new name for the condition long known as polycystic ovary syndrome, or PCOS. It affects hormones, metabolism (how the body uses energy), fertility, mental health and skin: common features include irregular or absent periods, higher levels of androgens (hormones such as testosterone) that can cause acne and unwanted hair, a higher risk of type 2 diabetes, and difficulty getting pregnant.
The old name pointed at the wrong thing. People with the condition don’t have more abnormal ovarian cysts, and it isn’t mainly an ovarian disorder [5]. In May 2026, after a 14-year international process led from Monash University in Melbourne and involving more than 22,000 survey responses, the name was changed in a paper published in The Lancet [1]. Of those surveyed, 86% of people with the condition and 71% of health professionals supported a name that describes what it actually does [5].
A name matters because it shapes what doctors look for. When the condition is seen as a fertility or “cyst” problem, its effects on metabolism and long-term health, such as the raised risk of type 2 diabetes, can be missed [2].
3.2×
15.3%
1 in 8
Up to 70%
Why it matters in Australia
The renaming was led from Australia [1], and the international PMOS guidelines, used in 195 countries, are also led from Monash University [6]. Australian data also show why the metabolic side matters: in a national study, women with PMOS were about three times as likely to develop type 2 diabetes, and the added risk was proportionally greatest in women who were not overweight [2]. That challenges the assumption that weight alone explains the risk.
The burden is not shared equally. The one Australian study of Aboriginal and Torres Strait Islander women found PMOS in about 15% of participants, rising to about 30% among women with obesity [3]. It was a single urban sample in Darwin from more than a decade ago, so better and more recent data are needed. Health professionals are moving to the new name over a three-year transition, with patient resources such as the government-funded AskPMOS app [5].
Global context
PMOS is common worldwide. The World Health Organization estimates that 10–13% of women of reproductive age have it, and that up to 70% of them are undiagnosed [4]. The international announcement of the new name put the number at around 170 million people [1]. Both describe the same global picture, so they are shown side by side rather than combined with the Australian figures above.
Sources
- PCOS name change: polycystic ovary syndrome renamed polyendocrine metabolic ovarian syndrome (media release on Teede HJ et al., The Lancet, 2026). Endocrine Society, 2026.
- The impact of obesity on the incidence of type 2 diabetes among women with polycystic ovary syndrome (Kakoly NS et al.). Diabetes Care, 42(4), 2019.
- Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia (Boyle JA et al.). Medical Journal of Australia, 196(1), 2012.
- Polycystic ovary syndrome (fact sheet). World Health Organization, 2026.
- PCOS renamed to better reflect multisystem condition. Medicine Today, 27(6), 2026.
- Polycystic ovary syndrome name change brings clarity to misunderstood condition (news). InSight+, Medical Journal of Australia, 2026.
Last reviewed: